Article
Targeting p130Cas- and microtubule-dependent MYC regulation sensitizes pancreatic cancer to ERK MAPK inhibition.
Cell reports - 29 Jun 2021
Waters Andrew M, Khatib Tala O, Papke Bjoern, Goodwin Craig M, Hobbs G Aaron, Diehl J Nathaniel, Yang Runying, Edwards A Cole, Walsh Katherine H, Sulahian Rita, McFarland James M, Kapner Kevin S, Gilbert Thomas S K, Stalnecker Clint A, Javaid Sehrish, Barkovskaya Anna, Grover Kajal R, Hibshman Priya S, Blake Devon R, Schaefer Antje, Nowak Katherine M, Klomp Jennifer E, Hayes Tikvah K, Kassner Michelle, Tang Nanyun, Tanaseichuk Olga, Chen Kaisheng, Zhou Yingyao, Kalkat Manpreet, Herring Laura E, Graves Lee M, Penn Linda Z, Yin Hongwei H, Aguirre Andrew J, Hahn William C, Cox Adrienne D, Der Channing J
Abstract excerpt
To identify therapeutic targets for KRAS mutant pancreatic cancer, we conduct a druggable genome small interfering RNA (siRNA) screen and determine that suppression of BCAR1 sensitizes pancreatic cancer cells to ERK inhibition. Integrative analysis of genome-scale CRISPR-Cas9 screens also identify BCAR1 as a top synthetic lethal interactor with mutant KRAS. BCAR1 encodes the SRC substrate p130Cas. We determine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.